+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma



An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma



Australasian Journal of Dermatology 47(1): 46-48



SUMMARY The short-term efficacy of imiquimod 5% cream for the treatment of primary superficial basal cell carcinoma has been established. This study investigated its efficacy following curettage (without electrodesiccation) for the treatment of primary nodular basal cell carcinoma on the trunk and limbs. Seventeen patients with a total of 34 lesions were enrolled. Curettage was used to de-bulk the lesion and confirm suitable histology. Lesions displaying more aggressive subtypes (such as micronodular or morpheoic components) were excluded. Lesions were treated daily for 6 to 10 weeks with imiquimod 5% cream. Three months post treatment all lesions were excised, and 32 of 34 treated lesions (94%) were histologically clear of basal cell carcinoma. Fourteen of 17 patients rated the cosmetic outcome of treatment as excellent or good. Curettage followed by imiquimod 5% cream is effective for the treatment of primary nodular basal cell carcinoma on the trunk and limbs, and most patients are pleased with the cosmetic outcome.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048240460

Download citation: RISBibTeXText

PMID: 16405483

DOI: 10.1111/j.1440-0960.2006.00222.x


Related references

Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. Journal of Drugs in Dermatology 6(9): 910-914, 2007

A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology 57(4): 616-621, 2007

Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatologic Surgery 32(1): 63-69, 2006

Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatologic Surgery 31(3): 318-323, 2005

Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial. Bmc Ophthalmology 15: 35, 2015

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology 138(9): 1165-1171, 2002

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream. Journal of Clinical and Aesthetic Dermatology 4(5): 39-43, 2011

A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. Journal of Drugs in Dermatology 7(1 Suppl 1): S7, 2008

Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatologic Surgery 30(3): 429-430, 2004

Imiquimod 5% Cream as Pre-Treatment of Mohs Micrographic Surgery for Nodular Basal Cell Carcinoma in the Face, A Prospective Randomized Controlled Study Imiquimod As Pre-Treatment of Mohs. 2012

The efficacy of imiquimod 5% cream (Aldara® in the treatment of aural plaque in horses: a pilot open-label clinical trial. Veterinary Dermatology 21(5): 503-509, 2010

Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma. Dermatology Nursing 21(2): 86-87, 2009

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. Indian Journal of Ophthalmology 65(1): 48-51, 2017

Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial. European Journal of Dermatology 17(5): 412-415, 2007

Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream. Dermatology Online Journal 14(2): 25, 2008